28/04/2022
EQS-News

Zur Rose Group AG: Shareholders approve all proposals

Zur Rose Group AG / Key word(s): AGMEGM
Zur Rose Group AG: Shareholders approve all proposals
28.04.2022 / 18:19

 
Frauenfeld, 28 April 2022
Press Release
 

Annual General Meeting 2022 of Zur Rose Group AG

Shareholders approve all proposals

The 29th Annual General Meeting of Zur Rose Group AG took place today. It was again held without the personal participation of shareholders. Shareholders were able to exercise their rights at the Annual General Meeting exclusively through the independent proxy. In total, 4,204,997 shareholder votes, corresponding to 37.1 per cent of the share capital or 62.7 per cent of the voting capital, were represented by the independent proxy.

The shareholders approved the management report, the annual and consolidated financial statements 2021, the appropriation of the balance sheet result, and ratified the actions of the Board of Directors and Executive Board from liability for their activities in the year under review. All proposals concerning the elections and re-elections to the Board of Directors and the Compensation and Nomination Committee were approved. Walter Oberhänsli was elected as Chairman of the Board of Directors and Rongrong Hu as a member of the Board of Directors and both were elected to the Compensation and Nomination Committee. The former Chairman of the Board of Directors, Prof. Stefan Feuerstein, is now serving as Vice Chairman. The Annual General Meeting approved the proposed maximum total amounts of compensation for the members of the Board of Directors and the Executive Board. In addition, the compensation report for the financial year 2021 was approved in a consultative vote. Ernst & Young AG was confirmed as auditors for a further term of office of one year. As of the next Annual General Meeting, Buis Bürgi AG, Zurich, will act as independent proxy.

Furthermore, the shareholders approved the proposals to create authorised share capital in the amount of 30 per cent of the registered share capital and to increase the conditional share capital for financing and other purposes to 20 per cent of the registered share capital. At the same time, they resolved that the upper limit of shares that can be issued under the restriction or exclusion of subscription rights or advanced subscription rights be limited to 10 per cent of the registered share capital. In addition, the Annual General Meeting approved the increase of the conditional capital for employee participations to 1.79 per cent of the registered share capital.

The minutes with the detailed voting results as well as a video message from Prof. Stefan Feuerstein and Walter Oberhänsli on the handover as Chairman will be available from 29 April, 2022 onwards at "zurrosegroup.com > Investors & Media > Annual General Meeting" or under this Link.

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Agenda
18 August 2022 Half-Year Results
20 October 2022 Q3 Trading Update

Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris, and employs more than 2,400 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving more than 12 million active customers in core European markets, Zur Rose generated external revenue of CHF 2,034 million in 2021.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care, as well as digital services relating to marketplaces, ecosystems, technology and telemedicine. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up and extending its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Its ambition is to provide customer-centred health journeys so people are offered optimum supply and a range of medication and treatment options. By doing so, Zur Rose is pursuing its vision of creating a world where people can manage their own health in one click.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.



End of Media Release



show this
Media Release (PDF)
Zur Rose Group
23/09/2022
Ad hoc News

Zur Rose Group announces a tender offer for all of its CHF 115 million outstanding bonds due 2023

Read more
Final allocations of
13/09/2022
Corporate News

Final allocations of Zur Rose approx. CHF 95 million Convertible Bonds Offering

Read more
Zur Rose Group
01/09/2022
Ad hoc News

Zur Rose Group successfully completes placement of approx. CHF 95 million Convertible Bonds and the approx. CHF 44 million Capital Increase by way of an accelerated book building process

Read more
Zur Rose Group
31/08/2022
Ad hoc News

Zur Rose Group launches approx. CHF 100 million Convertible Bonds and approx. CHF 50 million Capital Increase by way of an accelerated book building process

Read more
Zur Rose Group
18/08/2022
Ad hoc News

Zur Rose Group speeds up path to profitability and plans break-even at EBITDA level in 2023

Read more
Tobias Leipold, CEO
22/06/2022
Press-Release

Tobias Leipold, CEO and Co-Founder, leaves eHealth-Tec GmbH

Read more
01/06
Next